Coronavirus Update: Superior Tolerability Was Behind Pfizer/BioNTech’s Vaccine Switch
Far Fewer Suffered Fever Symptoms
Pfizer and BioNTech made a last-minute switch to new lead candidate ahead of a pivotal Phase II/III trial, in which 11,000 volunteers have now already been dosed worldwide.
